OBJECTIVE: To investigate the potential value of postoperative concurrent chemoradiation among patients with high-risk salivary gland carcinomas. DESIGN: Case control study based on retrospective medical record review. SETTING: A tertiary care comprehensive cancer center. PATIENTS: A total of 24 patients, 12 with major salivary gland carcinoma who were treated with postoperative concurrent chemoradiotherapy from 1998 to 2007 (chemoradiation group), and a control group of 12 patients treated with postoperative radiation alone. MAIN OUTCOME MEASURES: Overall survival, progression-free survival, toxic effects. RESULTS: All but 1 patient had stage III or IV disease; close or positive surgical margins were identified in 20 patients (83%). The median radiation dose was 63 Gy. In the chemoradiation group, platinum-based regimens were used in all. Treatment was well tolerated, but toxic effects, predominantly hematologic, were increased in the chemoradiation group. To date, 8 patients have died; the median overall survival was 53 months. The overall survival in the chemoradiation group was significantly better than in the radiation-alone group: 3-year survival rates were 83% and 44%, respectively (P = .05). CONCLUSIONS: Locally advanced or high-grade salivary gland carcinomas follow an aggressive clinical course. Based on our limited experience, postoperative chemoradiation with a platinum-based regimen seems to be effective in selected patients and warrants further investigation.
OBJECTIVE: To investigate the potential value of postoperative concurrent chemoradiation among patients with high-risk salivary gland carcinomas. DESIGN: Case control study based on retrospective medical record review. SETTING: A tertiary care comprehensive cancer center. PATIENTS: A total of 24 patients, 12 with major salivary gland carcinoma who were treated with postoperative concurrent chemoradiotherapy from 1998 to 2007 (chemoradiation group), and a control group of 12 patients treated with postoperative radiation alone. MAIN OUTCOME MEASURES: Overall survival, progression-free survival, toxic effects. RESULTS: All but 1 patient had stage III or IV disease; close or positive surgical margins were identified in 20 patients (83%). The median radiation dose was 63 Gy. In the chemoradiation group, platinum-based regimens were used in all. Treatment was well tolerated, but toxic effects, predominantly hematologic, were increased in the chemoradiation group. To date, 8 patients have died; the median overall survival was 53 months. The overall survival in the chemoradiation group was significantly better than in the radiation-alone group: 3-year survival rates were 83% and 44%, respectively (P = .05). CONCLUSIONS: Locally advanced or high-grade salivary gland carcinomas follow an aggressive clinical course. Based on our limited experience, postoperative chemoradiation with a platinum-based regimen seems to be effective in selected patients and warrants further investigation.
Authors: Naresh Jegadeesh; Yuan Liu; Roshan S Prabhu; Kelly R Magliocca; David M Marcus; Kristin A Higgins; Jeffrey M Vainshtein; J Trad Wadsworth; Jonathan J Beitler Journal: Oral Oncol Date: 2015-05-29 Impact factor: 5.337
Authors: Olga Micol Martínez; Elena Daghoum Dorado; María Dolores Amorós García; María Isabel Oviedo Ramírez; Isabel de la Fuente Muñoz; Jose Luis Fuster Soler Journal: Rare Tumors Date: 2016-10-06
Authors: Alexandra D Jensen; Anna V Nikoghosyan; Swantje Ecker; Malte Ellerbrock; Jürgen Debus; Klaus K Herfarth; Marc W Münter Journal: Radiat Oncol Date: 2011-11-02 Impact factor: 3.481
Authors: Brian J Gebhardt; James P Ohr; Robert L Ferris; Umamaheswar Duvvuri; Seungwon Kim; Jonas T Johnson; Dwight E Heron; David A Clump Journal: Am J Clin Oncol Date: 2018-09 Impact factor: 2.339
Authors: Moses Tam; Nadeem Riaz; Lucas Resende Salgado; Daniel E Spratt; Evangelia Katsoulakis; Alan Ho; Luc G T Morris; Richard Wong; Suzanne Wolden; Shyam Rao; Nancy Lee Journal: J Radiat Oncol Date: 2013-07-10